Altarac David 4
4 · Entasis Therapeutics Holdings Inc. · Filed Nov 6, 2019
Insider Transaction Report
Form 4
Altarac David
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2019-11-04+120,000→ 120,000 totalExercise: $5.70Exp: 2029-11-03→ Common Stock (120,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option shall vest on November 4, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.